BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for NOVAVAX, INC. · Biotechnology company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Maryland · House · Senate · $50,000.00 income · posted Jan 16, 2026

Lobbying activity 1

Health Issues

Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.